Researchers find new target deep within cancer cells

July 9, 2012, Cell Press

Investigators reporting in the July issue of the journal Cancer Cell have found that blocking a fundamental process deep within cancer cells can selectively kill them and spare normal cells.

For more than a century, clinicians have known that abnormalities of the —a small, rounded mass within the cell nucleus—can be diagnostic for cancer. The nucleolus is where certain genes are read to form the components of ribosomes, the cellular machines that make proteins. While abnormalities in the nucleolus are known to be diagnostic for cancer, researchers have wondered whether they are required for cells to become malignant.

Now have provided definitive evidence that accelerated reading of ribosomal genes is responsible for causing abnormal nucleoli and is necessary for the survival of cancer cells. They also show that blocking this accelerated reading in mice can set off a cascade of events that cause lymphoma and leukemia cells to die while sparing normal cells.

"The work in this study demonstrates that cancer cells are far more dependent on their ability to make ribosomes than normal cells. Critically, we demonstrate that selective inhibition of the enzyme, RNA polymerase I, that's responsible for synthesizing the major ribosomal components can be used to selectively kill cancer cells while leaving untouched," says senior author Dr. Ross Hannan, of the Peter MacCallum Cancer Centre in Australia. Previously, it was assumed that the ability to make ribosomes would be equally important to normal and .

The findings suggest that selective inhibitors of RNA polymerase I may be effective therapeutics for the treatment of human cancers. Based on the findings in this study, investigators will study one such inhibitor, Cylene Pharmaceuticals' CX-5461, in clinical trials at the Peter MacCallum Cancer Centre later this year.

Explore further: Research identifies how cancer cells cheat death

More information: Bywater et al.: "Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53." Cancer Cell. dx.doi.org/10.1016/j.ccr.2012.05.019

Related Stories

Research identifies how cancer cells cheat death

June 8, 2011
Research led by David Litchfield of The University of Western Ontario has identified how biochemical pathways can be "rewired" in cancer cells to allow these cells to ignore signals that should normally trigger their death. ...

Scientists discover nucleoli damage could kill cancer cells

November 8, 2011
(Medical Xpress) -- Damaging a cell’s nucleolus could destroy cancer cells by increasing levels of the most important tumour prevention protein, p53, reveals research presented at the National Cancer Research Institute ...

Recommended for you

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

Breast cancer gene does not boost risk of death: study

January 12, 2018
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.